We Sell One Enzyme Cleansing Powder. The Best-Documented Effects of Its Enzymes Were Measured in Factories, Not on Faces.
The tub sits by the tap. You tip a little powder into a wet palm, it goes grey-white and foamy, and somewhere on the packaging there is a sentence about enzymes digesting the dead skin off your face while you rinse.
We sell one of these. reve am's enzyme cleansing powder scored 9.8 in our screening, which puts it near the top of our catalogue, and all nineteen of its ingredient rows are graded low. Two of those nineteen rows are enzymes. Papain sits at position twelve. Lipase sits at eleven.
Lipase cuts fats. Papain cuts protein. Only one of those has anything to do with loosening dead keratinocytes, so we went looking for the trials behind the claim on the tub. What we found was a small pile of review articles pointing at each other, one 2008 federal enforcement notice, and a set of workplace exposure limits written in 1988.
Proteolytic enzymes almost certainly do something to the stratum corneum — that is basic protein chemistry. What does not exist is a body of controlled human trials showing that a rinse-off enzyme powder outperforms a plain cleanser, and the most recent review says so in plain language: clinical data are limited and there are no standardised experimental conditions. Meanwhile the two best-documented human effects of papain and its industrial cousins are an FDA enforcement action over 37 adverse event reports and decades of respiratory sensitisation in factory workers. Neither of those is a reason to throw out your powder. Both are a reason to stop pretending the exfoliation claim is settled.
What is actually in the tub
Nineteen rows. The first ten are, in order: corn starch, potassium myristate, microcrystalline cellulose, potassium cocoate, sorbitol, sodium cocoyl glycinate, silica, allantoin, aminopropyl ascorbyl phosphate and hydrolysed collagen. Two soaps and two powder bases before you reach anything that could be called an active.
Then papain and lipase. Then hyaluronate, glycerin, water, two pH adjusters and a soybean ferment extract.
So the honest description of this product is a soap-based powder cleanser that also contains enzymes, listed roughly two-thirds of the way down. Korea does not require percentages on cosmetic ingredient lists, and reve am does not volunteer any, so we cannot tell you whether the papain is 0.5% or 0.05%. We have asked suppliers for concentration figures before and been told the formula is proprietary. We have not yet asked this one.
The rest of our catalogue is worth a glance here too. Search all 1,920 ingredient rows across our 56 products for anything enzymatic and you get fourteen rows, and twelve of them are ferment filtrates — galactomyces, saccharomyces, bifida, lactobacillus, yeast, soybean. Those are fermentation broths. They are not purified proteases, whatever the marketing next to them implies, and we wrote about one of them at length in our galactomyces piece.
One product in fifty-six actually contains a protease.
The exfoliation evidence is thinner than the category is big
The most recent comprehensive review we could find is Venetikidou and colleagues, in Applied Sciences in 2025, covering the fruit proteases used in cosmetics, papain among them. It is enthusiastic. It describes enzymatic exfoliation as gentler than acids and appropriate for sensitive or acne-prone skin.
It also contains this sentence: recent clinical data are limited, and there are, as yet, no standardised data on the optimal experimental conditions.
That is a 2025 review telling you the field has no agreed protocol. Not a hostile critic — seven authors writing a paper about how promising these enzymes are.
The same review spends considerable space on a problem the marketing never mentions, which is that these enzymes are fragile. Bromelain is inactivated at pasteurisation temperatures and its thermal denaturation is irreversible. Papain and ficin need similar care. The authors note the enzymes are easily influenced by temperature, enzyme concentration and formulation stability, and may need additional stabilisation to hold their bioactivity. A dry powder is a sensible way to ship a protease, which is probably why the format exists at all. But nobody publishes the residual activity of the enzyme in the tub on your shelf after six months in a steamy bathroom, and we could not find a single product that prints an activity unit anywhere on the label.
We went looking for a randomised trial comparing an enzyme powder against the same powder with the enzyme left out. We did not find one. That does not mean none exists — our access to paywalled dermatology journals from this desk is patchy, and we say so every time it matters — but if such a trial were the backbone of the category, it would not be hard to find.
Papain has a regulatory file, and it is not about glow
On 23 September 2008 the FDA published an enforcement notice in the Federal Register, at 73 FR 54831, docket FDA-2008-N-0481. The subject was topical drug products containing papain — wound debridement ointments, the papain-urea kind used on ulcers and burns, not cosmetics.
The agency gave two reasons. Through January 2008 it had received 37 adverse event reports, including anaphylaxis and anaphylactic shock that started within 15 minutes of application, with hospitalisations and intensive care admissions. And it flagged cross-reactivity between papain and latex sensitivity. The second reason was the dearth of published well-controlled studies, which made it impossible to weigh benefit against risk. Manufacturing had to stop by 24 November 2008 and shipment by 21 January 2009.
Two things about this that we want to be careful with. Those products applied papain to open wounds at drug-strength concentrations, which is not what happens when you wash your face for forty seconds. And an adverse event report is a report, not a proven causal link. Neither caveat makes the file disappear. It is the largest single body of human safety data anyone has collected on topical papain, and it exists because of harm, not because of efficacy research.
Where these enzymes were actually measured on people
In 1969 workers at a Californian detergent plant were hospitalised after exposure to subtilisins, the bacterial proteases that had just been added to laundry powder. The plant had a working "safe limit" of 0.12 µg/m³ in place at the time; whether it was breached that day was never established.
What followed is one of the better-documented occupational allergy stories of the twentieth century. OSHA eventually set a ceiling limit for subtilisins of 0.06 µg/m³ — micrograms, not milligrams, which is an unusually small number for an industrial standard. In the study OSHA leaned on, Juniper and Roberts in 1984 found 3.7% of exposed workers had dose-related sensitisation symptoms: sweating, headache, chest pain, cough, breathlessness, wheeze. The same work identified dust level peaks, rather than low continuous exposure, as the prime cause of enzyme asthma episodes.
Papain is on that list too. Xaver Baur's 2013 compendium of causative agents of occupational asthma, in the Journal of Occupational Medicine and Toxicology, catalogues 520 different causes and places papain alongside various enzymes from Bacillus subtilis among agents with moderate evidence.
Sensitisation is not the same as reacting, though, and the food allergy literature makes that point sharply. Alessandri and colleagues, writing in Foods in 2023, tested 341 allergic patients in Italy against seven cysteine proteases. A third of them, 133 people, had IgE to at least one. Papaya papain came in at 1.5% and pineapple bromelain at 12%. And then: none of the subjects sensitised to the homologues from papaya, pineapple and fig reported allergy symptoms. The mite proteases were a different story — 96.38% of mite-sensitised patients had respiratory symptoms — but that is a different exposure route and a different protein load.
So a fruit protease can raise an antibody in 133 people without producing a single patient. What nobody has measured is what a forty-second rinse-off does to any of those numbers.
What our screening found
Our own grade on this product is soft in a way we should say out loud. We marked papain and lipase low risk with the function label "Enzyme Exfoliant", and our risk column has no field for respiratory route, no field for sensitisation versus irritation, and no field for whether a grade came from evidence or from caution. Papain is a documented occupational asthmagen in a peer-reviewed compendium and it is a powder in this product. That combination should be visible in our data and it is not — the same structural gap we admitted when the EU called tea tree a moderate sensitiser and our column had nowhere to record it. On the efficacy side, 9.8 out of 10 is a score for what is on the ingredient list, not a verdict on whether the enzymes do the job the tub says they do. They may. Nobody has run the trial that would tell us.
Reve:am Enzyme Cleansing Powder 70g
Nineteen ingredient rows, all graded low, no fragrance and no sulfates. Papain and lipase sit at positions twelve and eleven, and neither the percentage nor the residual enzyme activity is disclosed by the supplier.
The practical takeaway
Buy an enzyme powder because you like washing with a powder. That is a real reason. The format rinses clean, it travels without leaking, it lets a brand ship a protease without a preservative system holding it in water for two years, and a soap-and-starch base is a perfectly decent cleanser on its own merits.
Do not buy one because you have been told it is a gentler version of an acid. That comparison has not been run head to head in the way it would need to be, and we said something similar about the acids themselves in our salicylic acid piece. If your skin is reactive, the reasonable move is the same one that applies to every wash-off product: fewer variables, longer contact time only if nothing stings, and no new actives in the same week. Our double cleansing piece covers why the second wash usually matters less than people think.
If you are the person who reads ingredient lists — and if you are here, you are — the useful habit with any enzyme product is to check where the enzyme sits. Position twelve of nineteen tells you more than the word on the front. How we assign these grades in the first place is set out in our screening method, and the products that came through it best are on our awards page.
We will ask reve am for the papain concentration and the enzyme activity spec, and we will publish whatever comes back.
Including nothing.
- M. Venetikidou, E. Lykartsi, T. Adamantidi, V. Prokopiou, A. Ofrydopoulou, S. Letsiou, A. Tsoupras, "Proteolytic Enzyme Activities of Bromelain, Ficin, and Papain from Fruit By-Products and Potential Applications in Sustainable and Functional Cosmetics for Skincare," Applied Sciences 15(5):2637 (2025). Full text read.
- US Food and Drug Administration, "Topical Drug Products Containing Papain; Enforcement Action Dates," Federal Register 73(185):54831–54834, 23 September 2008; docket FDA-2008-N-0481. Full notice read.
- OSHA/NIOSH, "1988 OSHA PEL Project — Subtilisins," documenting the 0.06 µg/m³ ceiling limit and citing Juniper and Roberts (1984) and Thorne, Hillebrand, Magreni et al. (1986). Page read; the underlying 1984 and 1986 papers were not obtained.
- X. Baur, "A compendium of causative agents of occupational asthma," Journal of Occupational Medicine and Toxicology 8:15 (2013). Full text read.
- Alessandri et al., "Comparative Analysis of the Immune Response and the Clinical Allergic Reaction to Papain-like Cysteine Proteases from Fig, Kiwifruit, Papaya, Pineapple and Mites in an Italian Population," Foods 12(15):2852 (2023). Full text read.
- DHALIORA screening data: 56 products, 1,920 ingredient rows, full recount 2026-09-07. Fourteen rows match an enzyme or ferment-filtrate search; twelve are ferment filtrates and two are purified enzymes, both in the same product.
